When Low-Dose Naltrexone Triggers Insomnia: A Teaching Case on MCAS, POTS, Long COVID, and Medication Sensitivity - A Premium Blog Article
When Low-Dose Naltrexone Triggers Insomnia:
A Teaching Case on MCAS, POTS, Long COVID, and Medication Sensitivity
Yoon Hang Kim, MD, MPH
Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician
www.directintegrativecare.com
Introduction
In the landscape of complex chronic illness, clinicians frequently encounter patients whose physiology does not follow conventional pharmacokinetic expectations. Some individuals respond well to very small medication changes, while others develop significant symptoms even with seemingly trivial dose increases. This phenomenon is especially common among patients with overlapping conditions such as postural orthostatic tachycardia syndrome (POTS), suspected mast cell activation syndrome (MCAS), Long COVID, Ehlers-Danlos spectrum (EDS) features, attention deficit hyperactivity disorder (ADHD), endometriosis, and generalized medication sensitivity. [1,2,3]
This anonymized teaching case reviews an individual who initially benefited from low-dose naltrexone (LDN) but subsequently developed persistent sleep maintenance insomnia following dose escalation. The clinical discussion centered on how to safely pause, restart, dilute, and carefully titrate medication in the context of mast cell activation, histamine signaling, mitochondrial dysfunction, and nervous system sensitivity. Each section of this article presents a clinical teaching point relevant to clinicians managing medically complex patients.
The Clinical Problem: Benefit at Low Dose, Symptoms at Higher Dose
The individual in this case had been using LDN and initially tolerated lower doses well. However, after increasing to approximately 1.1 to 1.2 mg, the individual began experiencing regular nocturnal awakenings around 3:00 a.m. despite falling asleep without difficulty. Transitioning the dose to the morning did not resolve the insomnia. Sleep disturbance—particularly vivid dreams, insomnia, and nocturnal awakening—is a recognized side effect of LDN, reported in approximately 14 to 37 percent of patients in clinical trials. [4,5]
Teaching Point 1: Medication intolerance is not always an allergy or a simple side effect
In complex chronic illness, medication intolerance can reflect an activated immune or nervous system rather than a simple adverse drug reaction. A medication may be helpful at one dose but overstimulating at another. The concept of a narrow therapeutic window is particularly relevant in patients with suspected MCAS, Long COVID, POTS, or endorphin system dysregulation. [1,6] LDN works through transient opioid receptor blockade and modulation of Toll-like receptor 4 (TLR4) on microglial cells, both of which influence neuroimmune signaling. [4,7] When the system is already primed by underlying immune activation, even modest dose adjustments can cross a threshold into overstimulation.
Why Symptoms May Persist After Reducing the Dose
One confusing aspect of this case was that the insomnia did not immediately resolve when the individual reduced the LDN dose back to a previously tolerated level. This raised an important clinical question: why would a dose that was previously well tolerated now produce symptoms?
The explanation discussed was that once immune or histamine pathways are activated, the body may not immediately reset when the triggering stimulus is removed. Mast cell degranulation, for example, can initiate a cascade of mediator release—including histamine, prostaglandins, leukotrienes, and cytokines—that perpetuates inflammation and neural sensitization even after the initial trigger is withdrawn. [1,8]
Teaching Point 2: Once the system is activated, lowering the dose may not produce instant relief
A useful clinical analogy is the fire alarm: once triggered, the alarm continues to ring even after the original trigger has been removed. In mast cell activation or neuroimmune illness, the body may need a period of rest and stabilization before a medication can be reintroduced successfully. This is why the plan in this case was not simply to revert to the old dose. The safer strategy was to pause LDN entirely until baseline symptoms returned, then restart more carefully using precision titration.
The Role of Histamine and Mast Cell Activation in Sleep Disruption
The sleep disturbance in this case was hypothesized to be related to histamine pathway activation. Histamine is not solely an allergic mediator; it plays a critical role in the regulation of wakefulness. Histaminergic neurons, located exclusively in the tuberomammillary nucleus (TMN) of the posterior hypothalamus, project widely throughout the brain and are maximally active during waking hours, becoming silent during sleep. [9,10] Histamine acts through H1 receptors to promote cortical arousal, which is precisely why first-generation antihistamines are sedating. [10]
In individuals with suspected MCAS, excessive or inappropriate mast cell degranulation can produce elevated histamine levels at unpredictable intervals, potentially disrupting the normal circadian regulation of the histaminergic system. This may explain the characteristic pattern of sleep maintenance insomnia—the ability to fall asleep initially, followed by nocturnal awakening when histamine levels surge. Other symptoms commonly seen in MCAS, including flushing, palpitations, food reactivity, medication sensitivity, brain fog, and unexplained symptom flares, were also present in this individual. [1,8,11]
Teaching Point 3: MCAS is often a clinical diagnosis
Laboratory testing can be helpful in evaluating mast cell activation, but normal serum tryptase and other mast cell mediator levels do not rule out the diagnosis. The consensus-2 diagnostic framework proposed by Afrin and colleagues recognizes that many patients with clinically significant mast cell activation may not demonstrate laboratory abnormalities using currently available testing, particularly given the lability and short half-life of many mast cell mediators. [8,11] In practice, the diagnosis is frequently based on pattern recognition: multisystem symptoms consistent with mast cell mediator release, identifiable triggers, characteristic medication responses, and clinical improvement with mast cell–directed treatment. This clinical approach is especially relevant when someone presents with overlapping POTS, Long COVID, EDS-spectrum features, endometriosis, migraine, ADHD, or unexplained inflammatory symptoms. [1,2,3]
The Treatment Triad: LDN, Ketotifen, and Methylene Blue
The clinical framework discussed in this case included three therapeutic tools, each targeting a different aspect of the underlying pathophysiology:
Low-dose naltrexone (LDN) for immune modulation and endorphin support. LDN acts primarily through transient mu-opioid receptor blockade, leading to upregulation of endogenous opioid production (the “rebound effect”), as well as through inhibition of TLR4-mediated microglial activation, thereby reducing central neuroinflammation. [4,7]
Ketotifen as a mast cell stabilizer. Ketotifen is a dual-action agent that inhibits mast cell degranulation and blocks H1 histamine receptors. It has demonstrated efficacy in reducing visceral hypersensitivity, controlling anaphylaxis in systemic mastocytosis, and has anti-inflammatory properties that extend to eosinophil chemotaxis inhibition and suppression of interleukin-4 and interleukin-13 release from basophils. [12,13]
Methylene blue for mitochondrial support. At low doses, methylene blue functions as an alternative electron carrier in the mitochondrial electron transport chain, accepting electrons from NADH and donating them directly to cytochrome c, thereby bypassing dysfunctional Complex I and Complex III. This mechanism can sustain adenosine triphosphate (ATP) production and reduce reactive oxygen species (ROS) generation, providing neuroprotective and metabolic support. [14,15]
Teaching Point 4: LDN may help, but it may not be sufficient by itself
LDN can be a valuable tool for immune modulation, pain management, inflammation reduction, and neuroimmune dysregulation. However, if mast cells remain highly activated, LDN alone may not fully stabilize the system. In this case, ketotifen was discussed as a possible next step for the individual to review with a physician, with the goal of calming mast cell activity so that other treatments—including LDN—become easier to tolerate.
Why Precision Titration Matters
A major component of the management plan involved using dilution techniques to achieve extremely small dose changes. Instead of adjusting by 0.1 mg or more—a standard increment in most LDN titration protocols—the individual would use a dilution method allowing increases of approximately 1 microgram at a time. A practical example discussed was a 1:100 dilution strategy, in which a compounded LDN solution is further diluted so that each measured increment represents a fraction of the original dose.
Teaching Point 5: Sensitive patients may need micro-titration, not standard titration
Many medication titration schedules assume that patients can tolerate standard dose increases. However, in MCAS, POTS, Long COVID, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)-spectrum illness, or in the setting of a highly sensitized nervous system, even conventionally “small” changes may cross a symptomatic threshold. Micro-titration allows the clinician and patient to collaboratively identify the dose that provides benefit without triggering a flare. This approach demands patience but can be the difference between treatment success and unnecessary treatment abandonment.
The Restart Plan and the Importance of Stabilization
The agreed-upon plan was to pause LDN entirely until the individual returned to a personal symptom baseline. Once stable, the individual would restart at a previously tolerated dose. The plan also included considering split dosing—for example, 0.5 mg twice daily rather than a larger single dose—and, from there, using the dilution technique to increase very slowly, potentially by as little as 1 microgram per week.
Teaching Point 6: The first step after a flare is often stabilization, not escalation
When a patient is actively flaring, adding more treatment can sometimes create additional confusion regarding the source of symptoms. A deliberate pause allows the clinician and patient to determine whether symptoms are medication-driven, immune-driven, or part of the underlying illness pattern. Once the body returns to baseline, medication reintroduction becomes more informative and inherently safer.
Why Split Dosing May Improve Tolerability
Rather than taking the full LDN dose at once, the individual was advised to consider splitting the daily dose into two smaller administrations.
Teaching Point 7: Split dosing can reduce peak-related side effects
Some patients react not to the total daily dose but to the peak serum concentration achieved after a single administration. Splitting the dose may reduce peak effects and improve tolerability. For a medication-sensitive individual, 0.5 mg taken twice daily may produce a substantially different symptom profile than 1 mg taken once daily. This pharmacokinetic principle is well established for many drug classes and should be applied liberally in the management of medication-sensitive patients.
Long COVID, POTS, and the Neuroimmune System
The individual in this case also had Long COVID symptoms, including cognitive difficulty and post-exertional symptom exacerbation. The discussion emphasized that Long COVID is increasingly understood as a neuroimmune illness, affecting both the nervous system and the immune system through interconnected pathways. Neuroimaging studies have demonstrated neuroinflammation at the brainstem level, specifically at the dorsolateral inferior medulla—the anatomic location of the vagal nuclei and vestibular nuclei—in patients with both POTS and Long COVID. [16,17,18]
Serum autoantibodies reactive to G-protein-coupled adrenergic receptors have been identified in patients with both POTS and Long COVID-related dysautonomia, and elevated mast cell mediators including prostaglandins and plasma histamine have been documented in both conditions, suggesting shared neuroimmune mechanisms. [16,17]
Teaching Point 8: Long COVID is often a neuroimmune illness
Symptoms such as brain fog, fatigue, dysautonomia, palpitations, sleep disruption, food sensitivity, and post-exertional malaise can reflect nervous system and immune system dysregulation operating in concert. Both POTS and ME/CFS are now recognized as major phenotypes associated with Long COVID, with autonomic dysfunction present in nearly 70 percent of affected patients. [18] This is why treatment often requires a layered, multimodal approach rather than reliance on any single medication.
Exercise, Exertion, and Post-Exertional Malaise
The individual in this case had a background in competitive cycling and expressed a desire to return to activity. The recommendation was to avoid overexertion and consider supportive strategies—such as the use of a battery-assisted bicycle—to reduce the risk of post-exertional crashes.
Post-exertional malaise (PEM) is now recognized as a cardinal feature of ME/CFS and a prominent symptom in Long COVID. Pacing—the strategy of regulating activity to remain within one’s energy envelope and avoid triggering PEM—is the most widely recommended management approach, supported by a growing body of evidence. [19,20] Recent research has demonstrated that skeletal muscle structure is associated with lower exercise capacity in Long COVID patients, and that exercise-induced myopathy and metabolic disturbances worsen after induction of PEM. [20]
Teaching Point 9: In neuroimmune illness, “pushing through” can backfire
For patients with Long COVID, POTS, MCAS, or ME/CFS-spectrum symptoms, excessive exertion can worsen symptoms in ways that differ fundamentally from normal exercise recovery. The goal is not inactivity, but careful energy management. Exercise should support recovery rather than trigger relapse.
ADHD Medication Considerations in Complex Chronic Illness
The individual also inquired about Vyvanse (lisdexamfetamine) and whether it might interact with LDN or the broader treatment plan. The discussion noted that ADHD medication may be necessary for functional capacity, but treatment changes should be made cautiously, especially when adding agents that affect histamine, catecholamine, serotonin, or broader nervous system signaling pathways.
Teaching Point 10: Do not change too many variables at once
When a patient is medically complex, changing multiple medications or supplements simultaneously makes it difficult to determine what helped or harmed. A safer approach is to change one variable at a time, monitor carefully, document the response, and allow adequate washout or stabilization periods between changes. This principle is fundamental to rational polypharmacy management in integrative medicine.
Conclusion
This teaching case highlights an important principle in complex chronic illness care: the right medication can still cause problems if the dose, timing, or escalation speed does not match the individual’s physiology. For patients with suspected MCAS, POTS, Long COVID, EDS-spectrum features, endometriosis, ADHD, or high medication sensitivity, treatment often requires patience, precision, and a layered strategy.
The key teaching lessons are straightforward but clinically important:
Start low, go slow, and sometimes go even slower. Pause during flares before escalating treatment. Consider mast cell activation when insomnia, medication sensitivity, and autonomic symptoms overlap. Use micro-titration when standard titration proves too aggressive. Avoid changing multiple treatments simultaneously. Support the immune system, nervous system, and mitochondria together as an integrated whole.
This is not just about finding the “right dose.” It is about finding the dose the body can accept.
This blog was commissioned as a premium blog article.
For more information, please write to directintegrativecare@hush.com.
References
1. Kohn A, Chang C. The relationship between hypermobile Ehlers-Danlos syndrome (hEDS), postural orthostatic tachycardia syndrome (POTS), and mast cell activation syndrome (MCAS). Clin Rev Allergy Immunol. 2020;58(3):273–297.
2. Weinstock LB, Brook JB, Walters AS, et al. Association of postural orthostatic tachycardia syndrome, hypermobility spectrum disorders, and mast cell activation syndrome in young patients. J Allergy Clin Immunol. 2025;155(5 Suppl):AB168.
3. Chopra P. Ehlers-Danlos syndrome and associated conditions. The Ehlers-Danlos Society Educational Webinar. 2018.
4. Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. 2014;33(4):451–459.
5. Younger J, Noor N, McCue R, Mackey S. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis Rheum. 2013;65(2):529–538.
6. Patten DK, Schultz BG, Berlau DJ. The safety and efficacy of low-dose naltrexone in the management of chronic pain and inflammation in multiple sclerosis, fibromyalgia, Crohn’s disease, and other chronic pain disorders. Pharmacotherapy. 2018;38(3):382–389.
7. Toljan K, Vrooman B. Low-dose naltrexone (LDN)—review of therapeutic utilization. Med Sci (Basel). 2018;6(4):82.
8. Afrin LB, Self S, Menk J, Lazarchick J. Characterization of mast cell activation syndrome. Am J Med Sci. 2017;353(3):207–215.
9. Yoshikawa T, Nakamura T, Yanai K. Histaminergic neurons in the tuberomammillary nucleus as a control centre for wakefulness. Br J Pharmacol. 2021;178(4):750–769.
10. Thakkar MM. Histamine in the regulation of wakefulness. Sleep Med Rev. 2011;15(1):65–74.
11. Afrin LB, Ackerley MB, Bluestein LS, et al. Diagnosis of mast cell activation syndrome: a global “consensus-2.” Diagnosis (Berl). 2021;8(2):137–152.
12. Slapnicar CA, Smeenk CS, Hicks LK, Petrucci J, Vadas P, Trinkaus M. A retrospective case series describing the efficacy of ketotifen in systemic mastocytosis. Blood. 2018;132(Supplement 1):5474.
13. Klooker TK, Braak B, Koopman KE, et al. The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. Gut. 2010;59(9):1213–1221.
14. Tucker D, Lu Y, Zhang Q. From mitochondrial function to neuroprotection—an emerging role for methylene blue. Mol Neurobiol. 2018;55(6):5137–5153.
15. Rojas JC, Bruchey AK, Gonzalez-Lima F. Neurometabolic mechanisms for memory enhancement and neuroprotection of methylene blue. Prog Neurobiol. 2012;96(1):32–45.
16. Tavee J. Current concepts in long COVID-19 brain fog and postural orthostatic tachycardia syndrome. Ann Allergy Asthma Immunol. 2024;133(5):522–530.
17. Blitshteyn S. Neuroinflammation at the dorsolateral inferior medulla: a possible central nervous system localization for POTS and Long COVID. Biomedicines. 2025;13(1):166.
18. Kim Y, Che X, Bhatt A, et al. POTS, ME/CFS and Long COVID as neuroimmune disorders. Immunotargets Ther. 2026;15:23–42.
19. Sanal-Hayes NEM, McLaughlin M, Hayes LD, et al. A scoping review of ‘pacing’ for management of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): lessons learned for the long COVID pandemic. J Transl Med. 2023;21(1):701.
20. Appelman B, Charlton BT, Goulding RP, et al. Muscle abnormalities worsen after post-exertional malaise in long COVID. Nat Commun. 2024;15(1):17.
Disclaimer: This article is for educational and informational purposes only and does not constitute medical advice. The anonymized case presented is intended for clinical teaching. Individual treatment decisions should be made in consultation with a qualified healthcare provider. Mention of specific medications does not constitute an endorsement, and all therapeutic decisions should be individualized based on clinical context.
About the Author
Yoon Hang Kim, MD, MPH is board-certified in Preventive Medicine and is an Integrative and Functional Medicine physician with more than 20 years of clinical experience. He completed fellowship training through the University of Arizona’s Andrew Weil Center for Integrative Medicine as an Osher Fellow, holds board certification in Integrative and Holistic Medicine, and maintains certifications in medical acupuncture (UCLA) and preventive medicine, with advanced training through the Institute for Functional Medicine (IFM Scholar).
Dr. Kim’s clinical specialties include low-dose naltrexone (LDN) therapy, autoimmune disease, chronic pain, integrative oncology, fibromyalgia, chronic fatigue syndrome, mast cell activation syndrome, and mold toxicity. He is the author of three books and more than 20 published articles, with a particular focus on LDN and complex chronic illness.
Learn more at www.yoonhangkim.com | www.directintegrativecare.com
